Evidence map›Paper›PMID 34484852›Full record

ArticleACS catalysis2020

Enantioselective Synthesis of Chiral Amines via Biocatalytic Carbene N-H Insertion.

Viktoria Steck, Daniela M Carminati, Nathan R Johnson, Rudi Fasan

Open access · greenAbstract read
In one paragraph

Article in ACS catalysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 53 citations in OpenAlex.

  1. Protein engineering: status report.Protein engineering, design & selection : PEDS · 2026
    Review
  2. Review
  3. Designing Enzymatic Reactivity with an Expanded Palette.Chembiochem : a European journal of chemical biology · 2025
    Review
  4. Article
  5. Review
  6. Article
  7. First and second sphere interactions accelerate non-nativeChemical communications (Cambridge, England) · 2023
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Directed Evolution of Artificial Metalloenzymes in Whole Cells.Angewandte Chemie (International ed. in English) · 2022
    Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Viktoria SteckDepartment of Chemistry, University of Rochester, 14627 Rochester, New York, USA.
Daniela M CarminatiDepartment of Chemistry, University of Rochester, 14627 Rochester, New York, USA.
Nathan R JohnsonDepartment of Chemistry, University of Rochester, 14627 Rochester, New York, USA.
Rudi FasanDepartment of Chemistry, University of Rochester, 14627 Rochester, New York, USA.
University of Rochester · US

Funding

Selective P450 Oxidation Catalysts for Synthesis of Bioactive MoleculesR01GM098628 · NIGMS · UNIVERSITY OF TEXAS DALLAS · PI FASAN, RUDI · 2012 to 2024
$4.7M
NIGMS NIH HHS R01 GM098628
6 · The paper itself

Abstract

Optically active amines represent highly valuable building blocks for the synthesis of advanced pharmaceutical intermediates, drug molecules, and biologically active natural products. Hemoproteins have recently emerged as promising biocatalysts for the formation of C-N bonds via carbene transfer, but asymmetric N-H carbene insertion reactions using these or other enzymes have so far been elusive. Here, we report the successful development of a biocatalytic strategy for the asymmetric N-H carbene insertion of aromatic amines with 2-diazopropanoate esters using engineered variants of myoglobin. High activity and stereoinduction in this reaction could be achieved by tuning the chiral environment around the heme cofactor in the metalloprotein in combination with catalyst-matching and tailoring of the diazo reagent. Using this approach, an efficient biocatalytic protocol for the synthesis of a broad range of substituted aryl amines with up to 82%

Indexed as

asymmetric N—H insertioncarbene transferchiral aminesmyoglobinprotein engineering

Identifiers

PMID34484852
PMCPMC8412361
OpenAlexW3082520743

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.